Scientists have made a breakthrough in understanding the role of dopamine in schizophrenia by using advanced neuroimaging techniques to examine how the brain’s chemistry differs in those with the condition. Researchers applied a novel approach known as normative modelling to analyse dopamine function in individuals experiencing first-episode psychosis. The study, published in the journal Molecular Psychiatry, offers new insights into how dopamine abnormalities contribute to the disorder and suggests a potential method for predicting treatment response.
Schizophrenia is a complex psychiatric condition that affects millions worldwide, leading to symptoms such as hallucinations, delusions, and cognitive impairment. A longstanding theory in psychiatric research links the disorder to dysfunction in the brain’s dopaminergic system. By using molecular imaging methods, scientists have been able to measure dopamine synthesis capacity in individuals with schizophrenia and compare it with healthy control groups.
The study, conducted across multiple research sites, incorporated positron emission tomography (PET) imaging with the radiotracer [18F]FDOPA, which tracks dopamine synthesis. This approach enabled researchers to observe differences in dopamine activity across different brain regions. Traditionally, such studies have been limited by small sample sizes and variations in imaging protocols, making it difficult to draw reliable conclusions. However, by using normative modelling, the researchers accounted for these challenges and created a reference dataset based on healthy individuals. This allowed them to identify extreme deviations in dopamine function more precisely than ever before.
Findings revealed that individuals experiencing their first episode of psychosis exhibited significantly higher deviations in dopamine function compared to the control group. However, the pattern of these deviations varied among patients, reinforcing the idea that schizophrenia is a highly heterogeneous disorder. Notably, while previous research has suggested increased dopamine synthesis in the striatum, the study confirmed that abnormalities extend beyond this region, affecting broader neural circuits involved in psychosis.
The research also examined how these deviations relate to treatment responses. One of the key findings was that individuals with specific patterns of dopamine abnormality were more likely to respond positively to antipsychotic medication. By analysing data from multiple patient cohorts, scientists found that certain dopamine profiles were predictive of whether a patient would experience symptom reduction after receiving treatment. This predictive capability could help clinicians make more informed decisions when prescribing antipsychotic drugs, potentially reducing the trial-and-error approach that currently dominates schizophrenia treatment.
Beyond its immediate clinical implications, the study highlights the potential for using molecular imaging as a precision medicine tool in psychiatry. While PET imaging remains costly and logistically complex, the application of normative modelling offers a way to make the most of existing data and improve diagnostic accuracy. Future research will need to explore how these findings can be integrated into clinical practice and whether similar approaches can be used to study other psychiatric conditions linked to dopamine dysfunction.
